目的 探討固本益腸片聯(lián)合復方谷氨酰胺和曲美布汀治療腸易激綜合征的臨床療效。方法 收集2014年3月-2016年3月在上海市同仁醫(yī)院接受治療的腸易激綜合征患者86例，隨機分為對照組（43例）和治療組（43例）。對照組口服復方谷氨酰胺顆粒，1袋/次，3次/d，同時口服馬來酸曲美布汀片，0.1 g/次，3次/d。治療組在對照組的基礎上口服固本益腸片，4片/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組患者臨床療效，同時比較治療前后兩組患者腸道癥狀尺度表（BSS）評分、血漿生長抑素（SS）、血管活性腸肽（VIP）及胃動素（MTL）水平變化。結果 治療后，對照組和治療組總有效率分別為81.14%和95.35%，兩組總有效率比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者BBS總積分明顯低于同組治療前，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且與對照組治療后相比，治療組降低的更明顯，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者血漿SS、VIP和MTL水平均明顯降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組患者比對照組降低的更明顯，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 固本益腸片聯(lián)合復方谷氨酰胺和曲美布汀治療腸易激綜合征效果顯著，可明顯改善患者臨床癥狀及生活質量，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Guben Yichang Tablets combined with compound glutamine and trimebutine in treatment of irritable bowel syndrome. Methods Patients (86 cases) with irritable bowel syndrome in Shanghai Tongren Hospital from March 2014 to March 2016 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in control group were po administered with Compound Glutamine Granules, 1 bag/time, three times daily. And patients in control group were also po administered with Trimebutine Maleate Tablets, 0.1 g/time, three times daily. Patients in treatment group were po administered with Guben Yichang Tablets on the basis of the control group, 1 tablet/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the BSS scores, SS, VIP, and MTL levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in control and treatment groups were 81.14% and 95.35%, respectively, and there were differences between two groups (P<0.05). After treatment, the BBS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the BBS score in treatment group decreased more significantly than that in control group, with significant difference between two groups (P<0.05). After treatment, SS, VIP, and MTL levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). These indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Guben Yichang Tablets combined with compound glutamine and trimebutine have a significant clinical efficacy in treatment of irritable bowel syndrome, and can significantly improve the clinical symptoms and quality of life, which has a certain clinical application value.